[1] [1] DAS T, CHEN Z, HENDRIKS R W, et al. A20/Tumor necrosis factor -induced protein 3 in immune cells controls development of autoinflammation and autoimmunity: lessons from mouse models[J]. Front Immunol, 2018, 9: 104.

[2] [2] HERTENS P, VAN LOO G. A20: a jack of all trades[J]. Trends Cell Biol, 2024, 34(5): 360-362.

[3] [3] WERTZ I E, O'ROURKE K M, ZHOU H, et al. Deubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling[J]. Nature, 2004, 430(7000): 694-699.

[4] [4] KARRI U, HARASIMOWICZ M, CARPIO TUMBA M, et al. The complexity of being A20: from biological functions to genetic associations[J]. J Clin Immunol, 2024, 44(3): 76.

[5] [5] HAN D, LIU J, WANG Y, et al. Serum A20 level is associated with bone mineral density in male patients with type 2 diabetes mellitus[J]. Front Endocrinol, 2025, 16: 1490214.

[6] [6] GARRIDO A N, MACHHAR R, CRUZ-CORREA O F, et al. Single-cell RNA sequencing of circulating immune cells supports inhibition of TNFAIP3 and NFKBIA translation as psoriatic arthritis biomarkers[J]. Front Immunol, 2025, 16: 1483393.

[7] [7] WU Y, HE L, LI R, et al. A20 as a potential therapeutic target for COVID-19[J]. Immun Inflamm Dis, 2025, 13(1): e70127.

[8] [8] PHILIP R, ELHANI I, GALLOU S, et al. A20 haplo-insufficiency diagnosis beyond systemic lupus erythematosus: A systematic review of the literature[J]. Autoimmun Rev, 2025, 24(2): 103722.

[9] [9] MA Y, JIA R, CHEN S, et al. Ubiquitin-proteasome system in periodontitis: mechanisms and clinical implications[J]. Cell Proliferat, 2025, 58(3): e13781.

[10] [10] YANG S, CHEN K, YU J, et al. Inhibition of cathepsin L ameliorates inflammation through the A20/NF-B pathway in endotoxin-induced acute lung injury[J]. iScience, 2024, 27(11): 111024.

[11] [11] HE H, YANG Y, ZHANG X, et al. Regulation of Nrf2/A20/eEF1A2 Axis by ginsenoside Rb1: a key pathway in alleviating cerebral ischemia-reperfusion injury[J]. Discov Med, 2024, 36(187): 1743-1757.

[12] [12] MA A, MALYNN B A. A20: linking a complex regulator of ubiquitylation to immunity and human disease[J]. Nat Rev Immunol, 2012, 12(11): 774-785.

[13] [13] LIUWANTARA D, ELLIOT M, SMITH W S, et al. Nuclear factor-kappaB regulates beta-cell death: a critical role for A20 in beta-cell protection[J]. Diabetes, 2006, 55(9).

[15] [15] ROHM T V, MEIER D T, OLEFSKY J M, et al. Inflammation in obesity, diabetes and related disorders[J]. Immunity, 2022, 55(1): 31-55.

[16] [16] CATRYSSE L, FUKAYA M, SZE M, et al. A20 deficiency sensitizes pancreatic beta cells to cytokine-induced apoptosisin vitrobut does not influence type 1 diabetes developmentin vivo[J]. Cell Death Dis, 2015, 6(10): e1918.

[17] [17] SARKAR S A, KUTLU B, VELMURUGAN K, et al. Cytokine-mediated induction of anti-apoptotic genes that are linked to nuclear factor kappa-B (NF-kappaB) signalling in human islets and in a mouse beta cell line[J]. Diabetologia, 2009, 52(6): 1092-1101.

[18] [18] QIN Y J, ZHANG Z L, YU L Y, et al. A20 overexpression under control of mouse osteocalcin promoter in MC3T3-E1 cells inhibited tumor necrosis factor-alpha-induced apoptosis[J]. Acta pharmacol Sin, 2006, 27(9): 1231-1237.

[19] [19] HOU C L, ZHANG W, WEI Y, et al. Zinc finger protein A20 overexpression inhibits monocyte homing and protects endothelial cells from injury induced by high glucose[J]. Genet Mol Res, 2011, 10(2): 1050-1059.

[20] [20] SHRIKHANDE G V, SCALI S T, DA SILVA C G, et al. O-glycosylation regulates ubiquitination and degradation of the anti-inflammatory protein A20 to accelerate atherosclerosis in diabetic ApoE-null mice[J]. PloS One, 2010, 5(12): e14240.

[21] [21] CHEN T C, ZHU W H, WANG C Y, et al. ALK-BH5-mediated m6A modification of A20 regulates microglia polarization in diabetic retinopathy[J]. Front in Immunol, 2022, 13: 813979.

[22] [22] CHENG L Q, ZHANG D M, JIANG Y Z, et al. Decreased A20 mRNA and protein expression in peripheral blood mononuclear cells in patients with type 2 diabetes and latent autoimmune diabetes in adults[J]. Diabetes Res Clin Pr, 2014, 106(3): 611-666.

[23] [23] NT X, NL T, CV M, et al. Regulation of dendritic cell function by A20 through high glucose-induced Akt2 signaling[J]. J Recept Sig Transd, 2019, 39(5-6): 434-441.

[24] [24] L L, Y J, JJ S. TNFAIP3 is anti-inflammatory in the retinal vasculature[J]. Mol Vis, 2022, 28: 124-129.

[25] [25] SAHA A, BELLO D, FERNNDEZ-TEJADA A. Advances in chemical probing of protein O-GlcNAc glycosylation: structural role and molecular mechanisms[J]. Chem Soc Rev, 2021, 50(18): 10451-10485.

[26] [26] RATAJCZAK W, ATKINSON S D, KELLY C. A20 controls expression of beta-cell regulatory genes and transcription factors[J]. J Mol Endocrinol, 2021, 67(4): 189-201.

[27] [27] ZAMMIT N W, SEEBERGER K L, ZAMERLI J, et al. Selection of a novel AAV2/TNFAIP3 vector for local suppression of islet xenograft inflammation[J]. Xenotransplantation, 2021, 28(3): e12669.

[28] [28] YU L Y, LIN B, ZHANG Z L, et al. Direct transfer of A20 gene into pancreas protected mice from streptozotocin-induced diabetes[J]. Acta Pharmacol Sin, 2004, 25(6): 721-726.

[29] [29] LAYBUTT D R, KANETO H, HASENKAMP W, et al. Increased expression of antioxidant and antiapoptotic genes in islets that may contribute to beta-cell survival during chronic hyperglycemia[J]. Diabetes, 2002, 51(2): 413-423.

[30] [30] HAND L E, USAN P, COOPER G J S, et al. Adiponectin induces A20 expression in adipose tissue to confer metabolic benefit[J]. Diabetes, 2015, 64(1): 128-136.

[31] [31] DONATH M Y, SHOELSON S E. Type 2 diabetes as an inflammatory disease[J]. Nat Revi Immunol, 2011, 11(2): 98-107.

[32] [32] BAKER R G, HAYDEN M S, GHOSH S. NF-B, inflammation, and metabolic disease[J]. Cell Metab, 2011, 13(1): 11-22.

[33] [33] MEYEROVICH K, FUKAYA M, TERRA L F, et al. The non-canonical NF-B pathway is induced by cytokines in pancreatic beta cells and contributes to cell death and proinflammatory responsesin vitro[J]. Diabetologia, 2016, 59(3): 512-521.

[34] [34] ZAMMIT N W, GREY S T. Emerging roles for a20 in islet biology and pathology[J]. Adv Exp Med Biol, 2014, 809: 141-162.